tradingkey.logo

Caris Life Sciences Inc

CAI
查看详细走势图
22.000USD
+0.750+3.53%
收盘 02/06, 16:00美东报价延迟15分钟
6.21B总市值
亏损市盈率 TTM

Caris Life Sciences Inc

22.000
+0.750+3.53%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+3.53%

5天

-5.01%

1月

-23.56%

6月

-23.05%

今年开始到现在

-18.46%

1年

0.00%

查看详细走势图

TradingKey Caris Life Sciences Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Caris Life Sciences Inc当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值低估,在医疗设备与耗材行业排名58/205位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价37.89。中期看,股价处于下降通道。近一个月,市场表现非常差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Caris Life Sciences Inc评分

相关信息

行业排名
58 / 205
全市场排名
162 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看空

Caris Life Sciences Inc亮点

亮点风险
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
估值高估
公司最新PE估值-4.36,处于3年历史高位
乔治·索罗斯持仓
明星投资者乔治·索罗斯持仓,最新持仓市值55.65K

分析师目标

根据 9 位分析师
买入
评级
37.889
目标均价
+73.48%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Caris Life Sciences Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Caris Life Sciences Inc简介

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
公司代码CAI
公司Caris Life Sciences Inc
CEOHalbert (David Dean)
网址https://www.carislifesciences.com/
KeyAI